Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody [Yahoo! Finance]
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) [Yahoo! Finance]
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)